Log in
Enquire now
‌

Illimis Therapeutics

Illimis Therapeutics specializes in developing novel biologics based on its proprietary chimeric fusion protein platform. The platform aims to address neurodegenerative diseases such as Alzheimer's by utilizing TAM receptor-mediated phagocytosis, which reduces neuroinflammation

OverviewStructured DataIssuesContributors

Contents

illimistx.com/en/
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Drug discovery
Drug discovery
Biotechnology
Biotechnology
Location
South Korea
South Korea
Seoul
Seoul
B2X
B2B
B2B
CEO
‌
Sanghoon Park
Founder
‌
Chanhyuk Kim
‌
Wonsuk Chung
‌
Sanghoon Park
Number of Employees (Ranges)
11 – 50
Email Address
mgt@illimistx.com
Phone Number
+8224456877
Full Address
2F & 3F, 18, Heolleung-ro 569-gil, Gangnam-gu, Seoul 06376, Republic of Korea
Investors
Korea Development Bank
Korea Development Bank
‌
GS Ventures
‌
Woori Venture Partners
DSC Investment
DSC Investment
Aju IB Investment
Aju IB Investment
Total Funding Amount (USD)
42,000,000
Latest Funding Round Date
July 14, 2025
Latest Funding Type
Series B
Series B

Other attributes

Latest Funding Round Amount (USD)
42,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Illimis Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.